ANA BLAS GARCIA
PDI-Titular d'Universitat
PDI-Titular d'Universitat
Área de conocimiento: FISIOLOGIA
Departamento: Fisiología
Departamento: Fisiología
(9635) 44893
Asignaturas impartidas y modalidades docentes
Tutorías
| 01/09/2024 - 26/01/2025 |
| LUNES de 09:00 a 12:00 DESPATX (2-16) Planta 2 FAC. DE FARMÀCIA |
| 27/01/2025 - 31/07/2025 |
| LUNES de 11:00 a 14:00 SEMINARI Entresuelo planta baja FACULTAT DE MEDICINA I ODONTOLOGIA |
| Observaciones |
| Participa en el programa de tutorías electrónicas de la Universitat de València |
Publicaciones en revistas
- Polo M; Alegre F; Funes HA; Blas-García A; Víctor VM; Esplugues JV; Apostolova N. (2015) Mitochondrial (dys)function - a factor underlying the variability of EFV-induced hepatotoxicity?. British Journal of Pharmacology, 172(7), pp. 1713 - 1727 . ISSN: 0007-1188
- Apostolova N; Funes HA; Blas-García A; Alvarez A; Galindo MJ; Esplugues JV. (2015) Efavirenz and CNS - what we already know and questions that need to be answered. Journal of Antimicrobial Chemotherapy, 70(10), pp. 2693 - 2708. Review . ISSN: 0305-7453
- Apostolova N; Funes HA; Blas-García A; Alegre F; Polo M; Esplugues JV. (2015) Involvement of nitric oxide in the mitochondrial action of efavirenz: a differential effect on neurons and glial cells. Journal of Infectious Diseases, 211(12), pp. 1953 - 1958 . ISSN: 0022-1899
- Funes HA; Blas-García A; Esplugues JV; Apostolova N. (2015) Efavirenz alters mitochondrial respiratory function in cultured neuron and glial cell lines. Journal of Antimicrobial Chemotherapy, 70(8), pp. 2249 - 2254 . ISSN: 0305-7453
- Rovira-Llopis S, Díaz-Morales N, Bañuls C, Blas-García A, Polo M, López-Domenech S, Jover A, Rocha M, Hernández-Mijares A, Víctor VM. (2015) Is Autophagy Altered in the Leukocytes of Type 2 Diabetic Patients?. Antioxidants & Redox Signaling. ISSN: 1523-0864
- Blas-García A; Martí-Rodrigo A; Víctor VM; Polo M; Alegre F; Funes HA; Apostolova N; Esplugues JV. (2016) The purine analogues abacavir and didanosine increase acetaminophen-induced hepatotoxicity by enhancing mitochondrial dysfunction. Journal of Antimicrobial Chemotherapy, 71(4), pp. 916 - 926 . ISSN: 0305-7453
- Blas-García A; Apostolova N; Valls-Bellés V; Esplugues JV. (2016) Endoplasmic reticulum and mitochondria: independent roles and crosstalk in fatty liver diseases and hepatic inflammation. Current Pharmaceutical Design, 22(18), pp. 2607 - 2618. Review . ISSN: 1381-6128
- Ríos-Navarro C; De Pablo C; Collado-Díaz V; Orden S; Blas-García A; Martínez-Cuesta MA; Esplugues JV; Alvarez A. (2015) Differential effects of anti-TNF-alpha and anti-IL-12/23 agents on human leukocyte-endothelial cell interactions. European Journal of Pharmacology, 15(765), pp. 355 - 365 . ISSN: 0014-2999
- Blas-Garcia A; G. Baldovín H; Polo M; Victor VM; Garcia H; Herance JR (2016) Toxicological properties of two fluorescent carbon quantum dots with onion ring morphology and their usefulness as bioimaging agents. Rsc Advances. ISSN: 2046-2069
- Bañuls C; Rovira-Llopis S; Lopez-Domenech S; Diaz-Morales N; Blas-Garcia A; Veses S; Morillas C; Victor VM; Rocha M; Hernandez-Mijares A (2017) Oxidative and endoplasmic reticulum stress is impaired in leukocytes from metabolically unhealthy vs healthy obese individuals. International Journal of Obesity, 41(10), pp. 1556 - 1563 . ISSN: 0307-0565
- Perez IA; Blas-Garcia A; Carmona L; Esplugues JV. (2017) Ensuring the consistency of biosimilars. Current Pharmaceutical Design, 23(44), pp. 6733 - 6738 . ISSN: 1381-6128
- Alegre F; Moragrega ÁB; Polo M; Marti-Rodrigo A; Esplugues JV; Blas-Garcia A; Apostolova N. (2018) Role of p62/SQSTM1 beyond autophagy: a lesson learned from drug-induced toxicity in vitro. British Journal of Pharmacology, 175(3 ), pp. 440 - 455 . ISSN: 0007-1188
- Polo M; Alegre F; Moragrega AB; Gibellini L; Marti-Rodrigo A; Blas-Garcia A; Esplugues JV; Apostolova N. (2017) Lon protease: a novel mitochondrial matrix protein in the interconnection between drug-induced mitochondrial dysfunction and endoplasmic reticulum stress. British Journal of Pharmacology, 174(23), pp. 4409 - 4429 . ISSN: 0007-1188
- Apostolova N; Blas-Garcia A; Galindo MJ; Esplugues JV. (2017) Efavirenz: What is known about the cellular mechanisms responsible for its adverse effects. European Journal of Pharmacology, 812, pp. 163 - 173. Review. . ISSN: 0014-2999
- Milián L; Peris JE; Gandía P; Andújar I; Pallardó L; Górriz JL; Blas-García A. (2017) Tenofovir-induced toxicity in renal proximal tubular epithelial cells: involvement of mitochondria. AIDS. ISSN: 0269-9370
- Collado-Diaz V, Andujar I, Sanchez-Lopez A, Orden S, Blanch-Ruiz MA, Martinez-Cuesta MA, Blas-García A, Esplugues JV, Álvarez Á. (2018) Abacavir induces arterial thrombosis in a murine model. Journal of Infectious Diseases, 218(2), pp. 228 - 233 . ISSN: 0022-1899
- Martinez-Arroyo O; Gruevska A; Victor VM; González-Polo RA; Yakhine-Diop SMS; Fuentes JM; Esplugues JV; Blas-Garcia A; Apostolova N (2019) Mitophagy in human astrocytes treated with the antiretroviral drug Efavirenz: Lack of evidence or evidence of the lack. Antiviral Research, 168 , pp. 36 - 50 . ISSN: 0166-3542
- Martí-Rodrigo A, Alegre F, Moragrega ÁB, García-García F, Martí-Rodrigo P, Fernández-Iglesias A, Gracia-Sancho J, Apostolova N, Esplugues JV, Blas-García A. (2019) Rilpivirine attenuates liver fibrosis through selective STAT1-mediated apoptosis in hepatic stellate cells. Gut. ISSN: 0017-5749
- Hicks DF; Goossens N; Blas-García A; Tsuchida T; Wooden B; Wallace MC; Nieto N; Lade A; Redhead B; Dudley J; Lee YA; Hoshida Y; Friedman SL (2017) Transcriptome-based repurposing of apigenin as a potential anti-fibrotic agent targeting hepatic stellate cells. Scientific Reports, 7, p. 42563 . ISSN: 2045-2322
- García-Ruiz I; Blanes Ruiz N; Rada P; Pardo V; Ruiz L; Blas-García A; Valdecantos MP; Grau Sanz M; Solís Herruzo JA; Valverde ÁM (2019) Protein tyrosine phosphatase 1b deficiency protects against hepatic fibrosis by modulating nadph oxidases. Redox Biology, 26, p. 101263 . ISSN: 2213-2317
- Gruevska A; Moragrega ÁB; Galindo MJ; Esplugues JV; Blas-Garcia A; Apostolova N. (2020) p53 and p53-related mediators PAI-1 and IGFBP-3 are downregulated in peripheral blood mononuclear cells of HIV-patients exposed to non-nucleoside reverse transcriptase inhibitors. Antiviral Research, 178(104784) . ISSN: 0166-3542
- Tavernaro, Isabella;Martí-Rodrigo, Alberto;Kandziora, Maja;Kuntz, Sabine;Dernedde, Jens;Trautwein, Christian;Tacke, Frank;Blas-García, Ana;Bartneck, Matthias (2019) Modulating myeloid immune cell migration using multivalently presented monosaccharide ligands for advanced immunotherapy. Advanced Therapeutics, 2(12), p. 1900145 . ISSN: 2366-3987
- García-Martínez P; Collado-Díaz V; Mateu-Puchades A; Villarroel-Vicente C; Rovira-Llopis S; Blas-García A; Álvarez Á; Esplugues JV; Andújar I. (2020) Differential Effects of Biologics on Psoriasis-Related Vascular Inflammation and Risk of Thrombosis. Journal of Investigative Dermatology, 140(11), pp. 2294 - 2298 . ISSN: 0022-202X
- Lucantoni F; Martínez-Cerezuela A; Gruevska A; Moragrega ÁB; Víctor VM; Esplugues JV; Blas-García A; Apostolova N (2021) Understanding the implication of autophagy in the activation of hepatic stellate cells in liver fibrosis: are we there yet?. Journal of Pathology, 254(3), pp. 216 - 228 . ISSN: 0022-3417
- Daniel J. Klionsky; (múltiples autores); Nadezda Apostolova (múltiples autores); Rubén Artero; (múltiples autores); Ariadna Bargiela; (múltiples autores); Ana Blas-García; (múltiples autores); María Sabater; (múltiples autores); Victor M. Victor (múltiples autores) (2021) Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition). Autophagy, 17(1), pp. 1 - 382 . ISSN: 1554-8627
- Gruevska A; Moragrega ÁB; Cossarizza A; Esplugues JV; Blas-García A; Apostolova N. (2021) Apoptosis of Hepatocytes: Relevance for HIV-Infected Patients under Treatment. Cells, 10(2), p. 410 . ISSN: 2073-4409
- Benedicto AM; Fuster-Martínez I; Tosca J; Esplugues JV; Blas-García A; Apostolova N. (2021) NNRTI and Liver Damage: Evidence of Their Association and the Mechanisms Involved. Cells, 10(7), p. 1687 . ISSN: 2073-4409
- Lucantoni F; Benedicto AM; Gruevska A; Moragrega ÁB; Fuster-Martínez I; Esplugues JV; Blas-García A; Apostolova N. (2022) Implication of autophagy in the antifibrogenic effect of Rilpivirine: when more is less. Cell Death & Disease, 13(4), p. 385 . ISSN: 2041-4889
- Gruevska A; Moragrega ÁB; Galindo MJ; Esplugues JV; Blas-García A; Apostolova N. (2022) Down-Regulation of the Longevity-Associated Protein SIRT1 in Peripheral Blood Mononuclear Cells of Treated HIV Patients. Cells, 11(3), p. 348 . ISSN: 2073-4409
- Alegre F; Martí-Rodrigo A; Polo M; Ortiz-Masiá D; Bañuls C; Pinti M; Álvarez Á; Apostolova N; Esplugues JV; Blas-García A (2022) Macrophages Modulate Hepatic Injury Involving NLRP3 Inflammasome: The Example of Efavirenz. Biomedicines, 10(1), p. 109 . ISSN: 2227-9059
- Gallego-Durán R.; Albillos A.; Ampuero J.; Arechederra M.; Bañares R.; Blas-García A.; Berná G,; Caparrós E., Delgado T.C.; Falcón-Pérez J.M.; Francés R.; Fernández-Barrena M.G.; Graupera I.; Iruzubieta P.; Nevzorova Y.A.; Nogueiras R.; Macías R.I.R.; Martín F.; Sabio G.; Soriano G.; Vaquero J.; Cubero F.J.; Gracia-Sancho J. (2022) Metabolic-associated fatty liver disease: from simple steatosis toward liver cirrhosis and potential complications. Proceedings of the Third Translational Hepatology Meeting, organized by the Spanish Association for the Study of the Liver (AEEH). Gastroenterologia y Hepatologia, 45(9), pp. 724 - 734 . ISSN: 0210-5705
- Blas-García A.; Cubero F.J. (2022) Editorial: Advances in non-alcoholic fatty liver disease therapeutics: pathogenic mechanisms and targets. Frontiers In Pharmacology, 13, p. 1072353 . ISSN: 1663-9812
- Busca Arenzana C.; González-García J.; Blas-García A.; Esplugues J.V.; Olveira Martín A.; Montes Ramírez M.L. (2023) Benefits of rilpivirine for liver stiffness in HIV/HCV-coinfected patients. 2024 Feb;42(2):74-79. doi: 10.1016/j.eimce.2022.08.015. Epub 2023 Feb 1. Enfermedades Infecciosas y Microbiología Clínica (English Edition), 42 (2), pp. 74 - 79 . ISSN: 2529-993X
- Fuster-Martínez I; Català-Senent JF; Hidalgo MR; Roig FJ; Esplugues JV; Apostolova N; García-García F; Blas-García A. (2024) Integrated transcriptomic landscape of the effect of anti-steatotic treatments in high-fat diet mouse models of non-alcoholic fatty liver disease. Journal of Pathology, 262(3), pp. 377 - 389 . ISSN: 0022-3417
- Moragrega AB; Gruevska A; Fuster-Martínez I; Benedicto AM; Tosca J; Montón C; Victor VM; Esplugues JV; Blas-García A; Apostolova N (2023) Anti-inflammatory and immunomodulating effects of rilpivirine: Relevance for the therapeutics of chronic liver disease. Biomedicine & Pharmacotherapy, 167, p. 115537 . ISSN: 0753-3322
- Blas-García A; Apostolova N (2023) Novel therapeutic approaches to liver fibrosis based on targeting oxidative stress. Antioxidants, 12(8), p. 1567 . ISSN: 2076-3921
- Alvarado-Tapias E; Maya-Miles D; Albillos A; Aller R; Ampuero J; Andrade RJ; Arechederra M; Aspichueta P; Banales JM; Blas-García A; Caparros E; Cardoso Delgado T; Carrillo-Vico A; Claria J; Cubero FJ; Díaz-Ruiz A; Fernández-Barrena MG; Fernández-Iglesias A; Fernández-Veledo S; Francés R; Gallego-Durán R; Gracia-Sancho J; Irimia M; Lens S; Martínez-Chantar ML; Mínguez B, Muñoz-Hernández R, Nogueiras R; Ramos-Molina B; Riveiro-Barciela M; Rodríguez-Perálvarez ML; Romero-Gómez M; Sabio G; Sancho-Bru P; Ventura-Cots M; Vidal S; Gahete MD (2024) Proceedings of the 5th Meeting of Translational Hepatology, organized by the Spanish Association for the Study of the Liver (AEEH). Gastroenterologia y Hepatologia, 47(10), p. 502207 . ISSN: 0210-5705
- García-Martínez P; Gisbert-Ferrándiz L; Álvarez Á; Esplugues JV; Blas-García A. (2024) Bictegravir alters glucose tolerance in vivo and causes hepatic mitochondrial dysfunction. Antiviral Research, 231, p. 106020 . ISSN: 0166-3542
- Moragrega ÁB; Busca C; Apostolova N; Olveira A; Martín-Carbonero L; Valencia E; Moreno V; Bernardino JI; Abadía M; González-García J; Esplugues JV; Montes ML; Blas-García A. (2024) Rilpivirine Activates STAT1 in Non-Parenchymal Cells to Regulate Liver Injury in People Living with HIV and MASLD. Biomedicines, 12(7), p. 1454 . ISSN: 2227-9059
- Benedicto AM, Lucantoni F, Fuster-Martínez I, Diaz-Pozo P, Dorcaratto D, Muñoz-Forner E, Victor VM, Esplugues JV, Blas-García A, Apostolova N (2024) Interference with mitochondrial function as part of the antifibrogenic effect of Rilpivirine: A step towards novel targets in hepatic stellate cell activation. Biomedicine & Pharmacotherapy, 178, p. 117206 . ISSN: 0753-3322
- Abad-Jiménez Z; López-Domènech S; Pelechá M; Perea-Galera L; Rovira-Llopis S; Bañuls C; Blas-García A; Apostolova N; Morillas C; Víctor VM; Rocha M (2024) Calorie restriction modulates mitochondrial dynamics and autophagy in leukocytes of patients with obesity. Free Radical Biology and Medicine, S0891-5849(24), p. 00997-3 . ISSN: 0891-5849
Lineas de actividad
- Mecanismos celulares y moleculares implicados en la hepatotoxicidad inducida por fármacos antirretrovirales. . .
- Papel de los fármacos antirretrovirales en la aparición y/o progresión de la enfermedad de hígado graso no alcohólico. . .
- Identificación de nuevas dianas terapéuticas para la fibrosis hepática. . .
Participaciones en Congresos
- Alberto Martí-Rodrigo; Ángela B. Moragrega; Aleksandra Gruevska; Anabel Fernández-Iglesias; Jordi Gracia-Sancho; Juan V. Esplugues; Nadezda Apostolova; Ana Blas-García. 2019. Selective activation of STAT1-dependent apoptosis in hepatic stellate cells by rilpivirine as a new therapeutic option for liver fibrosis. . UEG (United European Gastroenterology) Week 2019 Barcelona. ESPAÑA.
- Martí-Rodrigo A; Moragrega ÁB; Gruevska A; Fernández-Iglesias A; Gracia-Sancho J, Esplugues JV, Apostolova N, Blas-Garcia A. 2019. Selective activation of Jak-Stat1-mediated apoptosis in hepatic stellate cells as a new therapeutic option for liver fibrosis: role of rilpivirine. . The International Liver congress - 54th Annual Meeting of the European Association for the Study of the Liver Viena. AUSTRIA.
- Federico Lucantoni, Aleksandra Gruevska, Ángela B. Moragrega, Juan V. Esplugues, Ana Blas-García and Nadezda Apostolova. 2020. The antiretroviral drug Rilpivirine alters autophagy in both quiescent and activated human stellate cells: novel targets for treatment of liver fibrosis. . II Congreso de Sefagia (Sociedad Española de Estudio de la Autofagia) Cáceres. ESPAÑA.
- Maria Luisa Montes; Carmen Busca; Angela B. Moragrega; Nadezda Apostolova; Antonio Olveira; Luz Martin Carbonero; Eulalia Valencia; Victoria Moreno; Jose I. Bernardino; Ignacio Perez-Valero; Juan González-García; Juan V. Espluges; Jose R. Arribas; Ana Blas-García. 2021. RPV activates STAT1 in stellate cells to regulate liver injury in PLWHIV and NAFLD. . Conference on Retroviruses and Opportunistic Infections (CROI) Virtual. ESTADOS UNIDOS DE AMÉRICA.
- Federico Lucantoni; David-Verdú Coloma; Alberto Martí-Rodrigo; Aleksandra Gruevska; Ángela B. Moragrega; Jordi Gracia-Sancho; Juan V. Esplugues; Nadezda Apostolova; Ana Blas-García. 2021. Rilpivirine and simvastatin exert a synergistic antifibrogenic effect in vitro on hepatic stellate cells through oxidative stress regulation. . International Workshop on Liver and Gut Fibrosis Valencia. ESPAÑA.
- Isabel Fuster-Martínez; José F. Català-Senent; Francisco J. Roig; Juan V. Esplugues; Nadezda Apostolova; Francisco García-García; Ana Blas-García. 2021. Transcriptomic signature of high fat diet murine models of NAFLD and its modulation by anti-steatotic treatments: a meta-analysis. . Digital NAFLD Summit 2021 Formato virtual. SUIZA.
- Ana Blas-García. 2019. Identificación de nuevas dianas farmacológicas para la fibrosis hepática: regulación de las rutas de señalización Jak-STAT1 y Jak-STAT3. . XIII Jornadas Científicas CIBERehd ESPAÑA.
- A. Martí-Rodrigo, Ángela B. Moragrega, P. Martí-Rodrigo, D. Castelli, N. Apostolova, Juan V. Esplugues, A. Blas-García. 2018. The antiretroviral rilpivirine induces hepatic regeneration in liver fibrosis and cirrhosis by modulating the STAT3/STAT1 balance. . The International Liver Congress 2018. 53rd annual meeting of the European Association for the Study of the Liver Paris. FRANCIA.
- A. Martí Rodrigo, A.B. Moragrega, P. Martí Rodrigo, D. Castelli, N. Apostolova, J.V. Esplugues, A. Blas-García. 2018. El antirretroviral Rilpivirina favorece la regeneración hepática en modelos in vivo de fibrosis y cirrosis a través de la activación de STAT3. . 43º Congreso Anual de la Asociación Española para el Estudio del Hígado Madrid. ESPAÑA.
- Federico Lucantoni; Aleksandra Gruevska; Ángela B. Moragrega; Alberto Martí-Rodrigo; Juan V. Esplugues; Ana Blas-García; Nadezda Apostolova. 2021. The hepatoprotective role of the antiretroviral drug Rilpivirine is associated with altered autophagy in in vitro and in vivo models of liver fibrosis. . International Liver Congress 2021 Virtual. SUIZA.
- Ángela B. Moragrega; Aleksandra Gruevska; Isabel Fuster-Martínez; Ana M. Benedicto; Federico Lucantoni; Juan V. Esplugues; Nadezda Apostolova; Ana Blas-García. 2021. Inhibition of CCL2/CCR2 signaling promotes rilpivirine-induced anti-fibrotic and anti-inflammatory effects in liver diseases. . International Workshop on Liver and Gut Fibrosis Valencia. ESPAÑA.
- Isabel Fuster-Martínez; José F. Catalá-Senent; Francisco J. Roig; Juan V. Esplugues; Nadezda Apostolova; Francisco García-García; Ana Blas-García. 2021. Transcriptomic signature of high fat diet murine models of NAFLD reveals a core set of liver fibrosis-promoting genes reversed by anti-steatotic treatments. . International Workshop on Liver and Gut Fibrosis Valencia. ESPAÑA.
- Ana M. Benedicto, Aleksandra Gruevska, Isabel Fuster-Martínez, Ángela B. Moragrega, Federico Lucantoni, Juan V. Esplugues, Ana Blas-García and Nadezda Apostolova. 2021. Molecular evidence of potential rilpivirine-induced regenerative effects in mouse models of liver injury. . International Workshop on Liver and Gut Fibrosis Valencia. ESPAÑA.
- Ana Blas-García. 2020. Ejemplo práctico real: reposicionamiento de fármacos para el tratamiento de la fibrosis hepática. . Jornadas de Hepatología Traslacional Online: Actualización en el estudio de las enfermedades hepáticas ESPAÑA.
- Aleksandra Gruevska; Ángela B. Moragrega; Federico Lucantoni; Joan Tosca; Cristina Montón; Juan V Esplugues; Ana Blas-Garcia; Nadezda Apostolova. 2021. IP-10/CXCL10: a potential target of the antiretroviral drug rilpivirine in liver fibrosis attenuation. . 3ª Reunión de Hepatología Traslacional Alicante. ESPAÑA.
- Ana Blas-García. 2021. Fibrosis regression: the example of the antiretroviral rilpivirine. . International Workshop on Liver and Gut Fibrosis ESPAÑA.
- Ana Blas-García. 2021. Comunicación intercelular de células estrelladas hepáticas en la progresión y regresión de la fibrosis. . I Jornadas Complutenses sobre Enfermedades Metabólicas ESPAÑA.
- Alegre F; Polo M; Martí-Rodrigo A; Moragrega A; Esplugues JV; Blas-García A; Apostolova N. 2017. p62/SQSTM1 in a drug-induced model of hepatotoxicity: a novel role beyond autophagy. . International Liver Congress Amsterdam . PAÍSES BAJOS.
- Ángela B. Moragrega; Alberto Martí-Rodrigo; Aleksandra Gruevska; Juan V. Esplugues; Nadezda Apostolova; Ana Blas-García. 2019. Rilpivirine-induced anti-inflammatory effects in liver diseases involve the activation of STAT6 signaling pathways in macrophages. . UEG (United European Gastroenterology) Week 2019 Barcelona. ESPAÑA.
- Martí-Rodrigo A; Alegre F; Polo M; Moragrega A; Apostolova N; Esplugues JV; Blas-García A. 2017. The anti-HIV drug rilpivirine decreases hepatic injury in a nutritional model of NAFLD through activation of the IL6/IL22-STAT3-p53 axis. . International Liver Congress Amsterdam . PAÍSES BAJOS.
- Martí-Rodrigo A; Alegre F; Moragrega AB; Polo M; Apostolova N; Esplugues JV; Blas-García A. 2017. The antiretroviral rilpivirine decreases hepatic inflammation and fibrosis progression in different experimental mice models of fibrosis. . The Liver Meeting 2017 (American Association for the Study of Liver Diseases) Washington . ESTADOS UNIDOS DE AMÉRICA.
- Martí-Rodrigo A; Alegre F; Polo M; Apostolova N; Esplugues JV; Blas-García A. 2016. Chronic administration of the non-nucleoside reverse transcriptase inhibitors efavirenz and rilpivirine decreases hepatic steatosis and fibrogenic response in a mouse model of NAFLD. . EASL Monothematic Conference: "Liver fibrosis: the next goal on targeted therapy?" Oporto. PORTUGAL.
- Alegre F; Polo M; Marti-Rodrigo A; Apostolova N; Esplugues JV; Blas-García A. 2015. Efavirenz alters the expression of inflammatory and fibrinogenic markers in hepatic stellate cells and liver tissue. . 17th International Workshop on Co-Morbidities and Adverse Drug Reactions in HIV Barcelona. ESPAÑA.
- Ángela B. Moragrega; Alberto Martí-Rodrigo; Aleksandra Gruevska; Juan V. Esplugues; Nadezda Apostolova; Ana Blas-García. 2019. Efecto anti-inflamatorio del antirretroviral Rilpivirina en la enfermedad hepática crónica. . 44º Congreso de la Asociación Española para el Estudio del Hígado (AEEH) Madrid. ESPAÑA.
- Alberto Martí-Rodrigo; Ángela B. Moragrega; Aleksandra Gruevska; Juan V. Esplugues; Nadezda Apostolova; Ana Blas-García. 2019. Rilpivirina reduce el daño hepático inducido por colestasis a través de la inactivación de células estrelladas hepáticas. . 1ª Reunión de Hepatología Traslacional: Status Quo y nuevos horizontes en el estudio del hígado San Sebastián. ESPAÑA.
- Ana Blas-García, Alberto Martí-Rodrigo, Ángela B. Moragrega, Aleksandra Gruevska, Nadezda Apostolova, Juan V. Esplugues. 2018. Rilpivirina como fármaco hepatoprotector en la progresión de la enfermedad hepática crónica. . XII Jornadas Científicas CIBERehd Barcelona. ESPAÑA.
- A. Blas-García, A. Martí Rodrigo, Á.B. Moragrega, P. Martí Rodrigo, D. Castelli, N. Apostolova, J.V. Esplugues Mota. 2018. El antirretroviral Rilpivirina reduce el daño hepático en un modelo nutricional de EHGNA a través de la resincronización del reloj circadiano hepático. . 43º Congreso Anual de la Asociación Española para el Estudio del Hígado Madrid. ESPAÑA.
- Martí-Rodrigo A; Alegre F; Miriam Polo; Moragrega A; Apostolova N; Esplugues JV; Blas-García A. 2017. El antiretroviral rilpivirina reduce el daño hepático en un modelo nutricional de HGNA a través de la activación del eje IL6/IL22-STAT3-P53 en células estrelladas. PREMIO AL MEJOR POSTER. . 42 Congreso Anual de la Asociación Española para el Estudio del Hígado Madrid. ESPAÑA.
- Alegre F; Martí-Rodrigo A; Miriam Polo; Moragrega A; Ortiz-Masia D; Pinti M; Apostolova N; Esplugues JV; Blas-García A. 2017. Los macrófagos hepáticos modulan el daño hepático agudo inducido por la activación del inflamasoma NLRP3: el ejemplo de Efavirenz. . 42 Congreso Anual de la Asociación Española para el Estudio del Hígado Madrid. ESPAÑA.
- Alegre F; Moragrega AB; Martí-Rodrigo A; Esplugues JV; Blas-García A, Apostolova N. 2017. P62 upregulation mediated through CHOP/DDIT3 is protective in a cell model of drug-induced hepatoxicity. . Second NEAR Meeting (Network of Excellence for Autophagy Research) Miraflores de la Sierra . ESPAÑA.
- Polo M; Moragrega AB, Alegre F; Martí-Rodrigo A; Blas-García A; Esplugues JV; Apostolova N. 2016. Novel function of mitochondrial Lon protease (LONP) in an Efavirenz-induced dual model of ER-stress and mitochondrial dysfunction in hepatic cells. . VIII Congreso Nacional de GESIDA San Sebastian. ESPAÑA.
- David Verdú-Coloma, Federico Lucantoni, Alberto Martí-Rodrigo, Aleksandra Gruevska, Ángela B. Moragrega, Jordi Gracia-Sancho, Juan V. Esplugues, Ana Blas-García and Nadezda Apostolova. 2020. A synergistic effect between Rilpivirine and Simvastatin in the context of liver fibrogenesis in vitro. . 45 Congreso Anual de la Asociación Española para el Estudio del Hígado (AEEH) Madrid. ESPAÑA.
- Angela B. Moragrega; Aleksandra Gruevska; Isabel Fuster-Martínez; Ana Benedicto; Federico Lucantoni; Juan V. Esplugues; Nadezda Apostolova; Ana Blas-García. 2021. Rilpivirine-induced anti-inflammatory effects in non-alcoholic fatty liver disease involve the inhibition of CCL2/CCR2 axis. . International Liver Congress 2021 Virtual. SUIZA.
Proyectos
- Nuevas dianas farmacológicas para el tratamiento de la enfermedad hepática crónica: rutas de señalización JAK-STAT1 y JAK-STAT3 como punto de partida (FIBROSTAT). 2019 - 2021. Ministerio de Ciencia, Innovación y Universidades. Secretaría de Estado de Investigación, Desarrollo e Innovación. . IP: Nadezda Apostolova y Ana Blas García.
- Identificación de nuevas dianas farmacológicas para la fibrosis hepática: regulación de las rutas de señalización Jak-STAT1 y Jak-STAT3. 2019 - 2020. CIBERehd. . IP: Ana Blas García.
- Estudio de la comunicación intercelular de células estrelladas hepáticas para identificar nuevas estrategias terapéuticas en la fibrosis hepática. 2021 - 2023. Conselleria d'Educació, Cultura i Esport. Generalitat Valenciana. . IP: Nadezda Apostolova y Ana Blas-García.
- Grupo miembro del Centro de investigación Biomédica en Red (CIBERehd). RENOVADO CADA AÑO. 2007 - 2018. Centro de Investigación Biomédica en Red (CIBER). . IP: Juan Vicente Esplugues Mota.
© 2025 UV. - Av. Blasco Ibáñez, 13. 46010 València. Espanya. Tel. UV: (+34) 963 86 41 00